Osteoclast Progenitors Reside in the Peroxisome Proliferator-Activated Receptor γ-Expressing Bone Marrow Cell Population

Wei Wei, Daniel Zeve, Xueqian Wang, Yang Du, Wei Tang, Paul C. Dechow, Jonathan M. Graff and Yihong Wan

Published Ahead of Print 26 September 2011.
Osteoclast Progenitors Reside in the Peroxisome Proliferator-Activated Receptor γ-Expressing Bone Marrow Cell Population

Wei Wei,1 Daniel Zeve,2 Xueqian Wang,1 Yang Du,1 Wei Tang,2 Paul C. Dechow,5 Jonathan M. Graff,2,3,4 and Yihong Wan1*

Department of Pharmacology,1 Department of Developmental Biology,2 Department of Molecular Biology,3 and Department of Internal Medicine,4 University of Texas Southwestern Medical Center, Dallas, Texas 75390, and Department of Biomedical Sciences, Baylor College of Dentistry, Texas A&M University Health Sciences Center, Dallas, Texas 752465

Received 21 July 2011/Returned for modification 20 August 2011/Accepted 18 September 2011

Osteoclasts are bone-resorbing cells essential for skeletal development, homeostasis, and regeneration. They derive from hematopoietic progenitors in the monocyte/macrophage lineage and differentiate in response to RANKL. However, the precise nature of osteoclast progenitors is a longstanding and important question. Using inducible peroxisome proliferator-activated receptor γ (PPARγ)-tTA TRE-GFP (green fluorescent protein) reporter mice, we show that osteoclast progenitors reside specifically in the PPARγ-expressing hematopoietic bone marrow population and identify the quiescent PPARγ+ cells as osteoclast progenitors. Importantly, two PPARγ-tTA TRE-Cre-controlled genetic models provide compelling functional evidence. First, Notch activation in PPARγ+ cells causes high bone mass due to impaired osteoclast precursor proliferation. Second, selective ablation of PPARγ+ cells by diphtheria toxin also causes high bone mass due to decreased osteoclast numbers. Furthermore, PPARγ+ cells respond to both pathological and pharmacological resorption-enhancing stimuli. Mechanistically, PPARγ promotes osteoclast progenitors by activating GATA2 transcription. These findings not only identify the long-sought-after osteoclast progenitors but also establish unprecedented tools for their visualization, isolation, characterization, and genetic manipulation.

Materials and Methods

Mice. PPARγ-tTA TRE-H2BGFP mice (46), flox-DTA mice (30), and NICD-flox mice (55) have been described previously. PPARγ-tTA TRE-cre mice were bred with flox-DTA mice to generate PTDTA mice. PPARγ-tTA TRE-cre mice were bred with NICD-flox mice to generate PTNICD mice. All experiments were performed using littermate cohorts. All protocols for mouse experiments were approved by the Institutional Animal Care and Use Committee of the University of Texas Southwestern Medical Center.

Bone analyses. To evaluate bone volume and architecture by micro-computed tomography (μCT), mouse tibiae were fixed in 70% ethanol and scanned using a Scanco μCT-35 instrument (Scanco Medical) at several resolutions for both overall tibial assessment (14-μm resolution) and structural analysis of trabecular and cortical bone (7-μm resolution). Trabecular bone parameters were calculated using the Scanco software to analyze the bone scans from the trabecular region directly distal to the proximal tibial growth plate. Histomorphometric analyses were conducted using Bioquant Image Analysis software (Bioquant). TRAP (tartrate-resistant acid phosphatase) staining of osteoclasts was performed using a leukocyte acid phosphatase staining kit (Sigma). ALP staining of

Bone is a dynamic tissue that constantly remodels itself by balancing osteoclast-mediated bone resorption and osteoblast-mediated bone formation. Osteoclasts derive from hematopoietic progenitors (5) in the monocyte/macrophage lineage (41, 47); in contrast, osteoblasts are of mesenchymal lineage (38). Physiological osteoclast functions are essential for skeletal development, homeostasis, and regeneration in response to injury. However, pathological increases in osteoclast activities are associated with several diseases, including osteoporosis, arthritis, and bone metastasis of cancers (35).

Osteoclast lineage specification is a multistep process that requires osteoclast progenitor commitment (41, 47), macrophage colony-stimulating factor (M-CSF)-mediated osteoclast precursor proliferation (57), and RANKL (receptor activator of NF-κB ligand)-mediated osteoclast differentiation (8, 29, 56). Although the discovery of RANKL has revolutionized research in osteoclast biology, RANKL mainly acts at later stages of osteoclastogenesis. The cellular identity and the precise nature of the osteoclast progenitors is a longstanding and important question. Using inducible peroxisome proliferator-activated receptor γ (PPARγ)-tTA TRE-GFP (green fluorescent protein) reporter mice, we show that osteoclast progenitors reside specifically in the PPARγ-expressing hematopoietic bone marrow population and identify the quiescent PPARγ+ cells as osteoclast progenitors. Importantly, two PPARγ-tTA TRE-Cre-controlled genetic models provide compelling functional evidence. First, Notch activation in PPARγ+ cells causes high bone mass due to impaired osteoclast precursor proliferation. Second, selective ablation of PPARγ+ cells by diphtheria toxin also causes high bone mass due to decreased osteoclast numbers. Furthermore, PPARγ+ cells respond to both pathological and pharmacological resorption-enhancing stimuli. Mechanistically, PPARγ promotes osteoclast progenitors by activating GATA2 transcription. These findings not only identify the long-sought-after osteoclast progenitors but also establish unprecedented tools for their visualization, isolation, characterization, and genetic manipulation.

Materials and Methods

Mice. PPARγ-tTA TRE-H2BGFP mice (46), flox-DTA mice (30), and NICD-flox mice (55) have been described previously. PPARγ-tTA TRE-cre mice were bred with flox-DTA mice to generate PTDTA mice. PPARγ-tTA TRE-cre mice were bred with NICD-flox mice to generate PTNICD mice. All experiments were performed using littermate cohorts. All protocols for mouse experiments were approved by the Institutional Animal Care and Use Committee of the University of Texas Southwestern Medical Center.

Bone analyses. To evaluate bone volume and architecture by micro-computed tomography (μCT), mouse tibiae were fixed in 70% ethanol and scanned using a Scanco μCT-35 instrument (Scanco Medical) at several resolutions for both overall tibial assessment (14-μm resolution) and structural analysis of trabecular and cortical bone (7-μm resolution). Trabecular bone parameters were calculated using the Scanco software to analyze the bone scans from the trabecular region directly distal to the proximal tibial growth plate. Histomorphometric analyses were conducted using Bioquant Image Analysis software (Bioquant). TRAP (tartrate-resistant acid phosphatase) staining of osteoclasts was performed using a leukocyte acid phosphatase staining kit (Sigma). ALP staining of

* Corresponding author. Mailing address: Department of Pharmacology, UT Southwestern Medical Center, 6001 Forest Park Road, Room ND8.502B, Dallas, TX 75390-9041. Phone: (214) 645-6062. Fax: (214) 645-6067. E-mail: yihong.wan@utsouthwestern.edu.

1 Published ahead of print on 26 September 2011.
FIG. 1. The osteoclast lineage resides in the PPARγ-expressing bone marrow population. (A) Schematic diagram of the PPARγ-tTA TRE-H2BGFP reporter mouse model. (B) Osteoclast marker expression in ex vivo bone marrow differentiation cultures (n = 3). V, vehicle; R, RANKL; B, BRL (rosiglitazone). The error bars indicate SD. (C and D) Osteoclast colony formation assay. Bone marrow cells were purified with a 40-μm cell strainer, FACS sorted into GFP− and GFP+ populations, and seeded at 100 cells/well. (C) Representative images of the TRAP-stained differentiation cultures. Scale bars, 25 μm. Two wells each for GFP− cells (left) and GFP+ cells (right) are shown; the second image from the left shows a GFP− well with no macrophage colony formation. (D) Average number of mature osteoclasts (Oc) per well (n = 96), showing that the frequency of osteoclast formation was 140-fold higher in the GFP+ population than in the GFP− population (P = 5.7 × 10−70). (E to G) The osteoclast lineage resides in the PPARγ-expressing bone marrow population in situ. (E) Multinucleated mature osteoclasts (outlined by dashed lines) differentiated from unsorted bone marrow of PPARγ-GFP mice ex vivo were GFP+. Scale bars, 25 μm. (F) CD115+ monocyte/macrophage precursors (Mo) in the bone marrow (BM) and CD115+ multinucleated osteoclasts at the bone/marrow boundary were GFP−. Scale bars, 4 μm. (G) The TRAP+ (purple) osteoclasts colocalized with the GFP+ cells in vivo (indicated by yellow arrowheads). Scale bars, 25 μm. (H and I) Microarray analysis of PPARγ+ (GFP+) and PPARγ− (GFP−) hematopoietic bone marrow cells (n = 2, from 2 independent reporter mice). (H) Scatterplot of the genes up- or downregulated in the GFP+ population (≥1.8-fold; P ≤ 0.05) (red). (I) Heat map illustrating the expression changes of cell-type-specific marker genes.
osteoclasts was performed using an alkaline phosphatase staining kit (Sigma). As a bone resorption marker, urinary C-terminal telopeptide fragments of the type I collagen (CTX-I) was measured with the RatLaps enzyme immunoassay (EIA) kit (Immunodiagnostic Systems) and normalized by urinary creatinine measured with the Infinity Creatinine Reagent (Thermo Scientific). As a bone formation marker, serum osteocalcin was measured with the mouse osteocalcin EIA kit (Biomedical Technologies Inc.).

Ex vivo osteoclast differentiation. Osteoclasts were differentiated from mouse bone marrow cells as described previously (52, 53). Briefly, bone marrow cells were purified with a 40-μm cell strainer to remove mesenchymal cells, differentiated with 40 ng/ml of M-CSF (R&D Systems) in α minimal essential medium (α-MEM) containing 10% fetal bovine serum (FBS) for 3 days and then with 40 ng/ml of M-CSF and 100 ng/ml of RANKL (R&D Systems) for 3 days (unless otherwise stated), with or without BRL (1 μM) throughout the time course. Mature osteoclasts were identified as multinucleated (>3 nuclei) TRAP+ cells. Osteoclast differentiation was quantified by the RNA expression of RANKL-induced transcription factors and osteoclast function genes using reverse transcription-quantitative PCR (RT-QPCR) analysis.

Osteoclast precursor proliferation assay. Osteoclast precursor proliferation was quantified using a bromodeoxyuridine (Brdu) cell proliferation assay kit (GE Healthcare Life Sciences) (6). Mouse bone marrow cells were treated with M-CSF (40 ng/ml) for 3 days to stimulate osteoclast precursor expansion. On day 4, the cells were M-CSF starved for 6 h to synchronize the cell cycle. The cells were then restimulated with M-CSF for 4 h to induce S phase, during which Brdu was provided in the culture medium and integrated into the DNA of the proliferating cells. Osteoclast precursor proliferation was quantified as BrdU incorporation using the BrdU enzyme-linked immunosorbent assay (ELISA) in the kit.

Gene expression analyses. RNA was reverse transcribed into cDNA using an ABI High Capacity cDNA RT Kit and analyzed using real-time quantitative PCR (SYBR green) in triplicate. All RNA expression was normalized by ribosomal protein L19.

Promoter analyses. Promoter sequence alignment was performed using Vector NTI Advanced 11 AlignX software (Invitrogen). Chromatin immunoprecipitation (ChIP) assays were performed using fluorescence-activated cell sorter (FACS)-sorted green fluorescent protein-positive (GFP+) and GFP− mouse bone marrow cells as previously described (52). The antibodies used were PPARγ, PU.1 (Santa Cruz), acetyl-histone H3 (Upstate/Millipore), and IgG (H9253). The FACS analyses of bone marrow cells were performed using an ABI High Capacity cDNA RT Kit and analyzed using real-time quantitative PCR (SYBR green) in triplicate. All RNA expression was normalized by ribosomal protein L19.

Flow cytometry. The FACS analyses of bone marrow cells were performed using a BD FACSscan flow cytometer and phycoerythrin (PE)-conjugated antibodies (all from BD Pharmingen). The FACS sorting of GFP+ and GFP− bone marrow cell populations was performed using a MoFlo Cell Sorter (Beckman Coulter).

Statistical analyses. All statistical analyses were performed with Student’s t-test, and the results are represented as means and standard deviations (SD).

RESULTS

Identification of osteoclast progenitors by in vivo labeling. To test this hypothesis, we employed our PPARγ-GFP reporter mice (PPARγ-TTA TRE-H2GBP) (46). In these mice, a tet transactivator cassette (tTA) was inserted into the endogenous PPARγ locus. When combined with the tTA-responsive H2GBP transgenic allele (TRE-H2GBP) (26, 51), the bigenic mice marked PPARγ-expressing cells with GFP (Fig. 1A). We isolated GFP+ cells from the hematopoietic bone marrow population by FACS (http://www.utsouthwestern.edu/wanlab/publications.htm) and compared their osteoclastogenic potential with that of GFP− cells using an ex vivo osteoclast differentiation assay. Expression of the osteoclast markers c-fos and TRAP (Fig. 1B), as well as Ctsk, Calc, and CAR2 (not shown), indicated that GFP+ cells differentiated into osteoclasts, while such activity appeared to be lacking in GFP− cells.

To quantify osteoclast colony formation, we sorted GFP+ and GFP− bone marrow cells, plated them at 100 cells/well in 96-well plates, and cultured them with M-CSF until 50% confluence before RANKL stimulation. After 11 days, we stained the cells for TRAP and quantified mature osteoclasts (TRAP+ and >3 nuclei) in each well. The majority of the GFP+ cells in each well had already formed osteoclasts, and the remaining mononuclear cells were TRAP− preosteoclasts in the process of maturation (Fig. 1C). For GFP+ wells, both macrophage and osteoclast colonies developed at 100% (96/96); in contrast, 55% (53/96) of GFP− wells developed TRAP+ macrophage colonies, and only 7% (4/96) formed osteoclasts. The number of osteoclasts per well was also significantly higher for GFP+ than for GFP− wells; as a result, the frequency of osteoclast formation was 140-fold higher for GFP+ cells (Fig. 1D), indicating that >99% of osteoclast progenitors/precurors were PPARγ+. These results show that the osteoclast lineage resides in the GFP+ bone marrow population ex vivo.

Imaging analyses further supported the notion that the osteoclast lineage was derived from GFP+ cells ex vivo and in vivo. First, we performed ex vivo osteoclast differentiation using the unsorted bone marrow cells of PPARγ-GFP mice. The multinucleated osteoclasts developed in culture were all GFP+ (Fig. 1E). Second, we performed immunostaining of the femoral sections for CD115 (M-CSF receptor [M-CSFR]), a marker for the monocyte/macrophage lineage. The CD115− multinucleated osteoclasts at the bone/marrow junction were GFP+, and notably, the CD115+ monocyte/macrophage precursors in the bone marrow also expressed GFP (Fig. 1F). Third, we performed TRAP staining as an independent method to identify osteoclasts. The TRAP+ osteoclasts also colocalized with GFP+ cells (Fig. 1G). We also observed GFP+ bone marrow cells that were TRAP−, which represent putative osteoclast progenitors and precursors (Fig. 1G). Thus, the osteoclast lineage resides in the GFP+ bone marrow population in situ.

To compare the gene expression profiles of GFP+ and GFP− cells, we performed microarray analysis. Approximately 800 genes were up- or downregulated in the GFP+ population by ≥1.8-fold (P ≤ 0.05) (Fig. 1H). The GFP+ cells displayed increased expression of stem cell/granulocyte-monocyte (GM) progenitor (26 genes) and macrophage/osteoclast (61 genes) markers and decreased expression of lymphocyte (20 genes), mast cell (37 genes), and megakaryocyte/erythocyte (128 genes) markers (Fig. 1I) (http://www.utsouthwestern.edu/wanlab/publications.htm). This suggests that (i) the PPARγ+ population is enriched for stem/progenitor cells and (ii) PPARγ expression specifically directs hematopoiesis toward the monocyte/macrophage lineage but away from lymphoid or other myeloid lineages, including megakaryocytes, erythrocytes, and mast cells. Consistently, methylcellulose colony-forming assays showed that GFP+ cells generated more macrophage colonies but fewer granulocyte, erythrocyte, and lymphocyte colonies than GFP− cells (http://www.4.utsouthwestern.edu/wanlab/publications.htm). Together, these data suggest...
indicate that we have identified the osteoclast progenitors in the PPARγ-expressing hematopoietic bone marrow cell population, and we can prospectively visualize, isolate, and characterize the osteoclast progenitors using the PPARγ-GFP reporter mice. Osteoclast progenitors reside in quiescent PPARγ+ bone marrow cells. The inducible PPARγ-tTA TRE-H2BGFP reporter mice afforded a tool for osteoclast stem/progenitor cell marking by H2BGFP label retention, a quality that is often indicative of quiescent stem/progenitor cell popula-
to assess their ability to differentiate into osteoclasts. The results showed that 94% of LRCs (+Dox) formed osteoclasts (90/96) whereas only 1% of GFP- cells (−Dox) formed osteoclasts (1/96) (Fig. 2D), indicating that the LRCs specifically labeled osteoclast progenitors.

We next further characterized the LRC (+Dox), GFP+ (−Dox), and GFP− (−Dox) populations by FACS analysis. First, LRCs represented ~1/3 of the total GFP+ cells (Fig. 2E). Second, stem/progenitor cell markers, including c-Kit (2, 24, 60), Sca-1 (44), CD135 (33), Siglec-F (3), and Notch-1 (6), were further enriched in the LRCs compared with either total GFP+ or GFP− (Fig. 2F) cells, whereas the macrophage marker CD11b was reduced in LRCs (Fig. 2F), indicating an increase in non-lineage-committed progenitors (4). Third, the erythrocyte marker Ter119 was excluded from both total GFP+ cells and LRCs (Fig. 2F). Fourth, >95% of LRCs expressed the leucocyte common antigen CD45, a marker found on all cells of hematopoietic origin except mature erythrocytes and platelets (23) but not on cells of mesenchymal origin (9), demonstrating that the LRCs purified by our method did not contain significant mesenchymal cell types (Fig. 2G). Fifth, 93% of total GFP+ cells and 85% of LRCs expressed CD115 (M-CSFR; c-fms), and 68% of total GFP+ cells and 12% of LRCs expressed CD265 (RANK), a receptor required for osteoclast precursors but not for myeloid progenitors or macrophages (15) (Fig. 2G). These results not only confirmed the microarray analysis (Fig. 1I) showing that the GFP+ population was highly enriched for the stem/progenitor cells of the monocyte/macrophage lineage, but also identified the LRC subpopulation as the osteoclast progenitors.

**Constitutive activation of Notch signaling in PPARγ+ cells causes high bone mass.** Notch signaling is a key regulator of osteoblastogenesis (17); however, the cell-autonomous function of Notch in osteoclastogenesis is incompletely understood. We found that Notch1 expression was 15-fold higher in LRCs than in total GFP+ cells (Fig. 2F), indicating that Notch signaling may regulate the quiescence-to-proliferation switch of the osteoclast progenitors. A previous study showed that loss of Notch function by Notch1 to -3 deletion enhances osteoclastogenesis by promoting osteoclast precursor proliferation (6). Nonetheless, the effect of gain of Notch function in the osteoclast lineage is unknown. Thus, if PPARγ+ cells are bona fide osteoclast progenitors, then Notch activation in these cells should impair osteoclastogenesis by restraining the quiescence-to-proliferation switch. To test this hypothesis, we ex-

---

**FIG. 3.** Notch activation in PPARγ-expressing cells causes high bone mass. (A) Schematic diagram of PTNICD mice. (B and C) qRT analysis of the tibiae from PTNICD or control mice (5 months old; male; n = 6). (B) Representative images of the trabecular bone of the tibial metaphysis (top; scale bar, 10 μm) and the entire proximal tibia (bottom; scale bar, 1 mm). Ctrl, control. (C) Quantification of trabecular bone volume and architecture. BS, bone surface; Tb.N, trabecular number; Tb.Sp, trabecular separation. The error bars indicate SD. (D) Urinary CTX-1 (normalized to urinary creatinine) (n = 6). (E) Serum osteocalcin (n = 6). (F and G) Bone histomorphometry (n = 6). (F) Representative images of TRAP-stained femoral sections. Scale bar, 100 μm. (G) Quantification of osteoclast surface (Oc.S/B.S) and number (Oc.N/B.Ar); B.Ar, bone area. (H) PTNICD mice exhibited extramedullary hematopoiesis in the spleen (n = 6). (I) Osteoclast precursor proliferation was decreased in the PTNICD cultures. (Left) Schematic diagram of the proliferation assay. (Right) Quantification of BrdU incorporation (n = 3). (J and K) Osteoclast differentiation was blunted in the PTNICD culture. (L) Representative images of TRAP-stained osteoclast differentiation cultures. Scale bar, 25 μm. (K) Representative osteoclast marker expression (n = 3). R, RANKL; V, vehicle; B, BRL. (L) N CID expression in control or PTNICD differentiation culture (n = 3). (M) Tibial RANKL/OPG mRNA ratio in control or PTNICD mice (n = 3). *P < 0.05; **P < 0.01; ***P < 0.005; ****, P < 0.001; ***** P < 0.0005; n.s., nonsignificant (P > 0.05).
exploited the PPARγ-tTA system, which enables not only osteoclast progenitor marking but also genetic manipulation therein. Specifically, PPARγ-tTA TRE-Cre mice permit rapid translation to in vivo models harboring flox-mediated inducible gene deletion or activation in osteoclast progenitors. To express a constitutively active Notch intracellular domain (NICD) in the osteoclast lineage, we bred PPARγ-tTA TRE-Cre mice with Stoplox/+NICD mice (55) to generate PTNICD mice (Fig. 3A).

Skeletal examinations indicated that the PTNICD mice developed high bone mass due to osteoclast defects. First, μCT imaging revealed a significant increase in trabecular bone in the PTNICD mice (Fig. 3B and C). Second, ELISA analyses showed that the bone resorption marker CTX-I was markedly decreased by 56% (Fig. 3D) while the bone formation marker osteocalcin was unaltered (Fig. 3E). Third, histomorphometry showed that osteoclast surface and number (Oc.S/B.S and Oc.N/B.Ar) were significantly reduced (Fig. 3F and G), while osteoblast surface and number (Ob.S/B.S and Ob.N/B.Ar) were unaltered (http://www4.uthwestern.edu/wanlab/publications.htm). As frequently observed in osteopetrotic mice, PTNICD mice also exhibited extramedullary hematopoiesis in the spleen (Fig. 3H). These data suggested that the increased bone mass resulted mainly from decreased osteoclast numbers and bone resorption.

To assess the stage at which Notch activation blocks osteoclastogenesis and the cell-autonomous nature of the effects, we analyzed the osteoclast progenitors ex vivo. M-CSF-mediated osteoclast precursor proliferation was markedly reduced in the PTNICD cultures (Fig. 3I). Consistently, the bone marrow cells from PTNICD mice exhibited lower expression of RANK, PPARγ1, and c-fms than controls (http://www4.uthwestern.edu/wanlab/publications.htm). Moreover, RANKL-mediated and BRL-stimulated osteoclast differentiation was also blunted (Fig. 3J), and induction of osteoclast marker genes was severely decreased (Fig. 3K). NICD expression was significantly increased (Fig. 3L). In contrast, theittal RANKL/OPG mRNA ratio was unaltered (Fig. 3M). These results all indicate that the impaired bone resorption in PTNICD mice was due to an osteoclast-autonomous defect. The simultaneous reduction in precursor proliferation and osteoclast differentiation suggested that Notch activation in PPARγ cells prevents the quiescence-to-proliferation switch of the osteoclast progenitors. This was consistent with the previous loss-of-function study showing that Notch is required to maintain the osteoclast stem cell fate (6). Importantly, these results demonstrated that osteoclast progenitors indeed reside in the PPARγ bone marrow population in vivo and can be marked and genetically manipulated by the PPARγ-tTA system.

Ablation of PPARγ cells causes high bone mass. To assess whether selective partial ablation of PPARγ cells by “diphtheria toxin attenuated” (DTA) (30) prevents osteoclastogenesis in vivo, we bred PPARγ-tTA TRE-Cre mice with Stoplox/+NICD DTA mice to generate PTDTA mice (Fig. 4A). We found that the PTDTA mice also exhibited high bone mass. μCT revealed higher trabecular bone mass (Fig. 4B and C). CTX-1 was 72% lower (Fig. 4D), while osteocalcin was unaltered (Fig. 4E). Osteoclast surface and numbers were decreased (Fig. 4F and G), while osteoblast surface and numbers were unaltered (http://www4.uthwestern.edu/wanlab/publications.htm). Consistently, the PTDTA mice also exhibited extramedullary hematopoiesis in the spleen (Fig. 4H). These data indicated that the increased bone mass in the PTDTA mice was mainly caused by decreased osteoclast numbers and bone resorption.

Because this bone phenotype may be contributed by other PPARγ-expressing cell types, such as adipocytes, we next investigated the cell-autonomous nature of the resorption defects by examining the osteoclastogenic potential of the bone marrow from PTDTA mice ex vivo. While many osteoclasts developed in control cultures, few formed in PTDTA cultures (Fig. 4I and J). This was due to cell ablation and, consequently, decreased BrdU incorporation (Fig. 4K). Thus, ablation of PPARγ cells severely blunted osteoclastogenesis and bone resorption. Together, the PTNICD and PTDTA genetic models provide compelling in vivo evidence that the osteoclast lineage resides in the PPARγ bone marrow population under physiological conditions.

Ovariectomy activation of osteoclast progenitors. Estrogen deficiency, from menopause or ovariectomy (OVX), is an important cause of osteoporosis and debilitating fractures. Current notions indicate that estrogen deficiency enhances osteoclast survival (27, 34), but its specific effects on osteoclast progenitors remain unknown. To track the response of the osteoclast lineage to estrogen loss, we performed sham operations or ovariectomies on PPARγ-GFP reporter mice in the setting of placebo or Dox-induced reporter suppression, coupled with BrdU labeling 24 h before FACS analysis (Fig. 5A). We found that OVX significantly increased the GFP+ bone marrow population by 3.8-fold (Fig. 5B). This increase appeared secondary to enhanced cell proliferation, as both the percentage of BrdU+ cells in the GFP+ population and the percentage of BrdU+/GFP+ cells in the entire bone marrow population were elevated by 1.8- and 6.4-fold, respectively (Fig. 5C and D).

Next, we examined the effects of OVX on osteoclast pro-
genitors (LRCs; +Dox) (Fig. 5E) and osteoclast precursors (total GFP+; +Dox) (Fig. 5F). We observed that the percentage of LRCs in total GFP+ cells (LRC/GFP+) was 15% in OVX mice compared to 66% in sham controls (66%), resulting in a 4.2-fold reduction (Fig. 5B). The percentage of stem cells (Notch-1) was decreased, while the percentage of progenitor cells (Sca1 or c-Kit) was increased (Fig. 5E and F). These results suggested that OVX triggered the quiescence-to-proliferation switch of the osteoclast progenitors. Furthermore, Siglec-F is predominantly expressed in immature myelomonocytic precursors, and its expression is reduced upon macrophage/osteoclast differentiation (3). We found that the percentage of Siglec-F+ cells was increased in the LRCs but decreased in the GFP+ population (Fig. 5E and F), suggesting that OVX triggered not only the proliferation of the LRC progenitors, but also the differentiation of the GFP+ precursors. This notion was further illustrated by the elevated percentage of monocyte/macrophage lineage-committed cells (CD11b+) (Fig. 5E and F). Moreover, osteoclast differentiation assays showed that when equal numbers of GFP+ cells were seeded, more osteoclasts formed for the OVX mice than for the sham-treated controls (Fig. 5G), indicating that OVX increased both the number of GFP+ cells in the bone marrow and their differentiation potential. Consequently, OVX led to increased resorption (Fig. 5H). Together, these results indicate that OVX activated both the quiescence-to-proliferation switch in osteoclast progenitors and the proliferation-to-differentiation switch in osteoclast precursors (Fig. 5I), revealing previously unrecognized effects of estrogen deficiency on early osteoclast lineage specification.

**Pharmacological activation of osteoclast progenitors.** The tracking system also allowed us to examine the response of the osteoclast lineage to drugs. As a model, we chose BRL, a PPARγ agonist and a diabetic drug that stimulates osteoclast differentiation and bone resorption (52, 53, 59). In ex vivo cultures, BRL attenuated M-CSF-mediated osteoclast precursor proliferation (Fig. 6A) yet exacerbated RANKL induction of osteoclast markers (c-fos and TRAP) (Fig. 6B), suggesting...
that PPARγ activation triggers a proliferation-to-differentiation switch toward osteoclasts. Interestingly, both BRL and RANKL suppressed the mature macrophage marker (MCP-1) (Fig. 6C), indicating that BRL promotes an osteoclast fate in part by shifting the progenitors away from a terminal macrophage fate.

To determine the effects of PPARγ activation on the osteoclast lineage in vivo, we next administered BRL or vehicle control to the reporter mice. By 2 weeks, BRL increased the GFP population within the marrow by 2.9-fold (Fig. 6D) yet reduced the percentage of stem/progenitor cells (Notch1, Sca-1, c-Kit, or CD135) in the GFP population (Fig. 6E). We did not observe changes in these markers in the GFP (PPARγ-) population, indicating that the BRL effects were PPARγ dependent (Fig. 6E). Consistently, BRL increased the macrophage lineage-committed cells (CD11b+) (Fig. 6F) (45). Intriguingly, BRL significantly diminished the percentage of mature macrophages in the GFP population, as both CD14 (a lipopolysaccharide [LPS] receptor) (21) and MCP-1 (58) were downregulated (Fig. 6G). In contrast, BRL increased the osteoclast surface (Fig. 6H) and the bone resorption marker CTX-1 (Fig. 6I), leading to a decreased bone volume/tissue volume (BV/TV) ratio (Fig. 6H) but unaltered bone mineral density (BMD) (not shown). These in vivo data were consistent with the ex vivo results (Fig. 6B and C), indicating that ligand activation of PPARγ triggered the osteoclast progenitors to differentiate.

**FIG. 6.** Ligand activation of PPARγ triggers osteoclast progenitors to differentiate. (A) BRL attenuated osteoclast precursor proliferation ex vivo (n = 3). The error bars indicate SD. (B and C) BRL stimulated RANKL-mediated induction of osteoclast markers (B) but inhibited mature macrophage markers (C) during a 6-day time course of ex vivo osteoclast differentiation (n = 3). The arrows indicate the addition of M-CSF at day 0 and the addition of M-CSF plus RANKL at day 3. (D to G) FACS analyses of the effects of BRL on osteoclast progenitors/precursors in vivo. PPARγ-GFP mice (6 months old; male; n = 4) were treated with BRL (10 mg/kg of body weight/day) or vehicle (Veh) for 1 or 2 weeks. (D) Percentages of GFP+ cells in bone marrow. (E) Percentages of cells expressing stem cell markers in GFP+ and GFP- populations. (F) Percentages of cells expressing pan-monocyte/macrophage marker. (G) Percentages of cells expressing mature macrophage markers. (H and I) Effects of BRL on osteoclast number and bone resorption in vivo. Mice were treated with BRL (10 mg/kg/day) or vehicle for 8 weeks (n = 4). (H) Osteoclast surface and BV/TV ratio. (I) Urinary CTX-1. (J) Model for BRL stimulation of osteoclast differentiation in vivo. (Left) The orange arrows indicate BRL-induced changes in each cell population. (Right) The orange triangle and the black trapezoid illustrate the relative subpopulation distributions in BRL- and Veh-treated mice. *, P < 0.05; **, P < 0.01; ***, P < 0.005; ****, P < 0.001; ******, P < 0.0001.
undergo differentiation, but toward osteoclasts and away from mature macrophages (Fig. 6J). Thus, PPARγ− cells are osteoclast progenitors, yet PPARγ is also a molecular switch that translates an increased local concentration of PPARγ agonists into enhanced osteoclast differentiation. Importantly, both OVX and BRL, representing pathological and pharmacological resorption-enhancing stimuli, triggered the PPARγ− cells to proliferate and differentiate, further supporting the notion that osteoclast progenitors reside in the PPARγ− bone marrow population in vivo.

PPARγ promotes osteoclast progenitors by activating GATA2 transcription. The GATA family of zinc finger transcription factors is an important regulator of hematopoiesis. GATA2 is required to generate osteoclast progenitors (50, 54), while GATA1 is dispensable for osteoclastogenesis but essential for erythropoiesis and megakaryocyte maturation (20, 37, 43). Therefore, the GATA2/GATA1 ratio in hematopoietic progenitors controls lineage divergence between osteoclasts and erythrocytes/megakaryocytes. In our microarray analysis, we found that this key GATA2/GATA1 ratio was 12.9-fold higher in the PPARγ− (GFP−) cells than in the PPARγ− (GFP+) cells (Fig. 7A), owing to elevated GATA2 expression and diminished GATA1 expression (Fig. 7B). Since PPARγ is also critical for osteoclastogenesis (52), it may promote osteoclast progenitor commitment by activating GATA2 transcription.

To test this hypothesis, we examined the GATA2 promoter and identified three highly conserved PPAR response elements (PPREs) (Fig. 7C). To determine whether PPARγ directly binds to the mouse GATA2 promoter and induces its transcription, we performed a ChIP assay with antibodies for PPARγ or acetylated histone H3, a chromatin marker for activated transcription. In GFP− cells, but not GFP+ control cells, PPARγ bound to all three PPREs in the mGATA2 promoter, accompanied by elevated levels of acetylated histone H3 (Fig. 7D); in contrast, PPARγ did not bind to the GATA1 promoter (not shown), suggesting that PPARγ inhibits GATA1 expression via an indirect mechanism. PU.1 binding was also detected in these GATA2 regions, suggesting that PPARγ colocalization with PU.1 in the GFP− cells specified GATA2 expression and osteoclast progenitors (Fig. 7D). We next assessed the functional requirement for GATA2 by both gain- and loss-of-function analyses. Ectopic GATA2 expression in PPARγ− cells to a level comparable to that in PPARγ+ cells partially rescued the osteoclast differentiation blockade (Fig. 7E). Conversely, GATA2 knockdown severely diminished both RANKL-mediated and BRL-stimulated osteoclast differentiation in the PPARγ− cells (Fig. 7F). Together, these results indicate that PPARγ promotes osteoclast progenitor commitment, at least in part, by directly binding to the GATA2 promoter and activating its transcription (Fig. 7G).

**DISCUSSION**

The cellular identity and precise nature of osteoclast progenitors are longstanding and important biological questions. Based on our cellular, molecular, genetic, pathological, and pharmacological evidence, in vivo and ex vivo, we conclude that the osteoclast lineage resides in the PPARγ+expressing hematopoietic bone marrow cell population, and we have identified the quiescent PPARγ− bone marrow cells as the osteoclast progenitors. Importantly, we have established PPARγ-tTA TRE-H2BGFP reporter mice as an unprecedented tool to visualize, isolate, quantify, and trace the lineage of osteoclast progenitors. As a complement, we have also established PPARγ-tTA TRE-Cre mice as a genetic tool to interrogate the function and regulation of osteoclast progenitors in vivo by inducing flox-mediated gene deletion or activation. Using these tools, we have uncovered previously unrecognized effects of ovariectomy and rosiglitazone, two resorption-enhancing stimuli, on the early osteoclast lineage. Mechanistically, we have identified GATA2 as a novel yet critical PPARγ target gene in osteoclast progenitors. Therefore, both conceptually and technically, this study opens an exciting new path to the fundamental understanding of both osteoclast lineage specification and PPARγ function.

In the PPARγ-tTA TRE-H2BGFP reporter mice, GFP+ cells also label adipocyte progenitors and mature adipocytes (46). Intriguingly, several reports show that mammalian cells of the adipocyte lineage and the macrophage lineage share numerous functional and antigenic properties. Gene expression profiling revealed that preadipocytes share a surprisingly closer signature with macrophages than with adipocytes, and preadipocytes can be effectively converted to macrophages in a macrophage environment (10). This appears to be an evolutionarily conserved phenomenon, because in invertebrates, such as Drosophila, hemocytes (blood cells) and fat bodies also share the expression of fate-determining genes (14). Our findings that PPARγ− cells label both adipocyte progenitors and macrophage/osteoclast progenitors provided mechanistic evidence for convergence and/or plasticity in the adipocyte and macrophage lineage specification. Together with the dual roles of PPARγ ligand in stimulating both adipogenesis and osteoclastogenesis, our findings illuminate a potential molecular basis for the close correlation between insulin-sensitizing effects and bone loss effects, as well as the emerging connections between fat and bone.

Stem/progenitor cells are defined as multipotent; hence, in order to target osteoclast progenitors experimentally, it is impossible to completely rule out other differentiation outcomes, and specificity is only relative. For example, Tie2 labels not only osteoclast progenitors, but also all other hematopoietic progenitors, as well as endothelial cells (13, 52), whereas PPARγ labels osteoclast and adipocyte progenitors but not other hematopoietic lineages (Fig. 1 and 2). The advantages of the PPARγ-tTA-based mouse models include the following: (i) they distinguish macrophages/osteoclasts from other hematopoietic lineages; (ii) they target the entire osteoclast lineage, including osteoclast progenitors and mature osteoclasts; and (iii) they permit temporal control of inducible cell labeling and genetic manipulations in the osteoclast lineage. Our results show that osteoclast progenitors are 140-fold enriched in the PPARγ− bone marrow cell population, and thus, only <1% of osteoclast progenitors may be derived from PPARγlow or PPARγ+ cells. Moreover, previous studies have documented that Notch activation in lymphoid progenitors causes T-cell lymphoblastic leukemia in humans and mice (16, 36). In our study, PTNICS mice did not develop lymphoma, which further supports the notion that PPARγ specifically directs hematopoiesis toward the monocyte/macrophage lineage and that the
FIG. 7. PPARγ promotes osteoclast progenitors by activating GATA2 transcription. (A) GATA2/GATA1 mRNA ratio in GFP− and GFP+ bone marrow populations (n = 2). The error bars indicate SD. (B) GATA2 and GATA1 mRNA expression (n = 2). (C) Alignment of mouse (m), rat (r), and human (h) GATA2 promoter PPRE regions, together with known PPREs for ap2, PEPCK, ACS, and DR-1 consensus. (D) ChIP analysis of PPARγ or PU.1 binding and histone H3 acetylation in the mGATA2 promoter PPRE regions in GFP− and GFP+ bone marrow cells. For P values, the asterisks (or n.s.) compare each antibody with IgG control in the same cell population; the pluses compare the same antibody in GFP− cells with GFP+ cells (n = 3). (E) Osteoclast differentiation blockade in PPARγ− cells was partially rescued by ectopic GATA2 expression. Hematopoietic bone marrow cells were transfected with GATA2-expressing plasmid or vector control. Osteoclast differentiation was quantified by TRAP expression (left), and GATA2 protein was quantified by Western blotting (IB) (right). The P values compare GATA2-transfected GFP− cells with vector-transfected GFP− cells; GFP− cells served as a positive control. (F) RANKL-induced and BRL-stimulated osteoclast differentiation in PPARγ− cells was severely diminished by GATA2 knockdown. Hematopoietic bone marrow cells were transfected with GATA2 siRNA (siGATA2) or control siRNA (siCtrl). Osteoclast differentiation was quantified by TRAP expression (left), and GATA2 protein was quantified by Western blotting (right). The P values compare siGATA2-transfected GFP− cells with siCtrl-transfected GFP− cells; GFP− cells served as a negative control. (G) Model for PPARγ regulation of osteoclastogenesis. PPARγ expression promotes osteoclast progenitor specification by activating GATA2 transcription. Upon PPARγ agonist availability, the ligand-activated PPARγ/RXRα receptor complex recruits coactivator PGC1β and induces c-fos transcription, thereby stimulating RANKL-mediated osteoclast differentiation. HSC, hematopoietic stem cells. * or +, P < 0.05; ** or ++, P < 0.01; *** or ++++, P < 0.0005; **** or ++++++, P < 0.0001; n.s., nonsignificant (P > 0.05).
PPARγ-expressing bone marrow population does not contain lymphoid progenitors. Since PPARγ also labels adipocyte progenitors (46), it is possible that Notch constitutive activation in PTNICD mice may also affect other PPARγ− cells, such as adipocytes, in addition to osteoclast progenitors.

Several drivers targeting macrophage precursors or mature osteoclasts have been elegantly described; nonetheless, because they do not target osteoclast progenitors, they are not suitable for in vivo study of early osteoclast lineage specification. For example, CD11b or lysozyme drivers are useful to target macrophage precursors because they are upregulated only upon macrophage differentiation (12, 19, 25). In addition, Ctsk or TRAP drivers are useful to target preosteoclasts and mature osteoclasts because they are upregulated only upon osteoclast differentiation (11, 34). Therefore, the PPARγ−TA-based models represent a novel osteoclast progenitor-targeting strategy that is complementary to other existing models for the comprehensive investigation of osteoclast lineage specification and differentiation.

Indeed, the PTNICD and PTDTA genetic models provide compelling in vivo evidence that the osteoclast lineage resides in the PPARγ− bone marrow population under physiological conditions; in particular, the PTNICD model supports the notion that PPARγ− cells represent osteoclast progenitors. In the PTDTA model, the DTA was an “attenuated” version of diphtheria toxin, thus explaining the relatively mild bone phenotype, which was supported by the survival of the PTDTA mice in contrast to the embryonic lethality in the global PPARγ knockout (KO) mice (7, 28, 40). Furthermore, both OVX and BRL, representing pathological and pharmacological resorption-enhancing stimuli, triggered the PPARγ− cells to proliferate and differentiate, further supporting the notion that osteoclast progenitors reside in the PPARγ− bone marrow population in vivo. The rapid increase (1 to 2 weeks) in the percentage of GFP− bone marrow cells in response to BRL treatment in vivo indicates that this effect was not likely secondary to any BRL alteration of adipocytes followed by changes in hematopoeisis, which takes at least 4 weeks (1).

The Ets family transcription factor PU.1 is essential for the development of both myeloid and B-lymphoid cells (42). This suggests that additional transcription factors are required to function in combination with PU.1 and confer lineage specificity (22). Since osteoclasts are of myeloid lineage, PU.1 is also essential for the generation of osteoclast progenitors. Indeed, PU.1 deletion in mice precludes osteoclast development, leading to arrested bone resorption and osteopetrosis (47). A recent study revealed that, in macrophages, PPARγ colocalizes with PU.1 in areas of open chromatin and histone acetylation near a distinct set of hematopoietic genes (31). Our results suggest that in the PPARγ− cells, PPARγ cooperates with PU.1 to activate the transcription of a subset of genes, including GATA2, thereby directing macrophage/osteoclast lineage commitment. In contrast, in the PPARγ− cells, the absence of PPARγ prevents GATA2 transcription and alters the subset of genes regulated by PU.1, thereby directing B-lymphoid lineage commitment. Therefore, our identification of PPARγ− bone marrow cells as osteoclast progenitors provides in vivo evidence for the notion that the collaborative interaction between PPARγ and PU.1 on a subset of promoters is essential to activate the transcriptional program required for macrophage/osteoclast lineage commitment. Furthermore, our results suggest that the expression of PPARγ, rather than the ligand activation of PPARγ, promotes osteoclast progenitor specification by enhancing GATA2 expression, which is downregulated during the quiescence-to-proliferation switch and thus is absent in osteoclast precursors (53a) (Fig. 7G). Together, our current and previous studies reveal that PPARγ plays dual roles in osteoclastogenesis that involve multiple mechanisms and target genes (Fig. 7G): PPARγ expression promotes osteoclast progenitors by inducing GATA2, and PPARγ ligand activation stimulates osteoclast differentiation by inducing c-fos.

ACKNOWLEDGMENTS

We thank J. Zerwekh for assistance with bone histomorphometry, L. Smith for assistance with μCT, and D. Mangelsdorf and S. Kliwer for helpful discussion. This work was supported by the University of Texas Southwestern Medical Center Endowed Scholar Startup Fund (Y.W.), a BD Biosciences Research Grant Award (Y.W.), CPRIT (RP100841 [Y.W.]), the March of Dimes (5-FY10-1 [Y.W.]), The Welsh Foundation (J-1751 [Y.W.]), NIH (R01 DK089113 [Y.W.] and R01 DK066556, R01 DK064261, and R01 DK088220 [J.M.G.]), and a postdoctoral fellowship (W.T.) and a predoctoral fellowship (D.Z.) from the American Heart Association South Central Affiliate. Y.W. is a Virginia Murchison Linthicum Scholar in Medical Research. J.M.G. is a founder of Reata Pharmaceuticals. We declare that we have no financial conflict of interest.

REFERENCES


This work was supported by the University of Texas Southwestern Medical Center Endowed Scholar Startup Fund (Y.W.), a BD Biosciences Research Grant Award (Y.W.), CPRIT (RP100841 [Y.W.]), the March of Dimes (5-FY10-1 [Y.W.]), The Welsh Foundation (J-1751 [Y.W.]), NIH (R01 DK089113 [Y.W.] and R01 DK066556, R01 DK064261, and R01 DK088220 [J.M.G.]), and a postdoctoral fellowship (W.T.) and a predoctoral fellowship (D.Z.) from the American Heart Association South Central Affiliate. Y.W. is a Virginia Murchison Linthicum Scholar in Medical Research. J.M.G. is a founder of Reata Pharmaceuticals. We declare that we have no financial conflict of interest.

Downloaded from http://mcb.asm.org/ on November 8, 2011 by UNIV TEXAS SW MED CTR 904

Vol. 31, 2011

PPARgamma MARKS OSTEOCLAST PROGENITORS 4705